Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company LifeSpan Biosciences Inc. (LSBio) has acquired Cambridge, UK-based Biorbyt, provider of bioreagents for research laboratory use. Terms of the transaction were not disclosed.
Biorbyt (www.biorbyt.com) serves the global scientific research community with products that include primary and secondary antibodies, proteins, ELISA kits, an extensive range of small molecules, enzymes and peptides, and research tools such as IHC IF IP kits and reagents, and cells and lysates.
According to Bob Dunn, Managing Director, TSCP, “The acquisition of Biorbyt brings us one step closer to our goal of making LSBio the world’s leading provider of biomaterials for medical research.” Added Mr. Dunn, “We’re pleased to welcome Biorbyt, its management and exceptional personnel into the LifeSpan Biosciences family.”
